Which of the following antiplatelet drugs is a P2Y12 receptor blocker not effected by CYP2C19 polymorphism:
Correct Answer: Prasugrel
Description: Prasuagrel is a third-generation thienopyridine antiplatelet agent that binds irreversibly to the P2RY12 receptor and inhibits ADP-mediated platelet activation and aggregation. The pharmacokinetics of prasuagrel&;s active metabolite is not known to be effective by genetic variations in CYP2C19 genotype. P2Y12 receptor Blockers P2Y12 Receptor Blockers are a group of Anti-platelet agents that inhibit the binding of ADP to its receptors on platelets and inhibit platelet aggregation. Inhibit the activation of the GP IIb/IIIa receptors required for platelets to bind to fibrinogen and to each other. P2Y12 receptor belongs a group of G-protein-coupled (GPCR) purinergic receptors that are chemoreceptor for adenosine diphosphate (ADP) Irreversible (Thienopyridines) Reversible (Cyclopentyltriaolo-pyrimidines) Ticlopidine (oral) (First generation) Clopidogrel (Oral) (Second generation) Prasugrel (Oral) (Third Generation) Ticagrelor (Oral) Cangrelor (Intravenous) Ref: Goodman and Gilman 13th edition Pgno: 597
Category:
Pharmacology
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now